Search

Your search keyword '"Cefaclor pharmacology"' showing total 276 results

Search Constraints

Start Over You searched for: Descriptor "Cefaclor pharmacology" Remove constraint Descriptor: "Cefaclor pharmacology"
276 results on '"Cefaclor pharmacology"'

Search Results

1. Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity.

2. Root canal dressings for revascularization influence in vitro mineralization of apical papilla cells.

3. Coordination and redox interactions of β-lactam antibiotics with Cu 2+ in physiological settings and the impact on antibacterial activity.

4. Biophysical control of the growth of Agrobacterium tumefaciens using extremely low frequency electromagnetic waves at resonance frequency.

5. Use of platelet-rich plasma for regeneration in non-vital immature permanent teeth: Clinical and cone-beam computed tomography evaluation.

6. Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin Synergy.

7. Characterization and antibiotic susceptibility of Streptococcus agalactiae isolates causing urinary tract infections.

8. Covalent inhibition of New Delhi metallo-β-lactamase-1 (NDM-1) by cefaclor.

9. Synthesis, spectral and antibacterial sudies of copper(II) tetraaza macrocyclic complexes.

10. Evaluation of cefaclor oral suspensions stability using reversed phase high performance liquid chromatography and antimicrobial diffusion methods.

11. Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus.

12. Evaluation of disk diffusion methods to detect low-level β-lactamase-negative ampicillin-resistant Haemophilus influenzae.

13. Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1.

14. blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.

15. [A simple disk diffusion test to identify beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae--application of cephalexin, cefsulodin and cefaclor disks].

16. Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.

17. In vitro antimicrobial activity of cefditoren and other oral antibiotics against Streptococcus pneumoniae, isolated from children with community acquired respiratory tract infections.

18. Pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers.

19. Immunomodulatory properties of cefaclor: in vivo effect on cytokine release and lymphoproliferative response in rats.

20. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters.

21. In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora.

22. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].

23. Reassessment of cefaclor breakpoints for Haemophilus influenzae.

24. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.

25. Reassessment of the cefaclor breakpoint for Streptococcus pneumoniae.

26. PK-PD modelling of the effect of cefaclor on four different bacterial strains.

27. Detection of penicillin-binding protein 2b gene alteration in Streptococcus mitis by polymerase chain reaction.

28. [Susceptibility of Branhamella catarrhalis to antibiotics].

29. Beta-lactam resistance in Streptococcus mitis isolated from saliva of healthy subjects.

30. Microbiological analysis of infected root canals from symptomatic and asymptomatic teeth with periapical periodontitis and the antimicrobial susceptibility of some isolated anaerobic bacteria.

31. Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor.

32. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].

33. An unusual abdominal mass in a renal transplant recipient.

34. [The influence of medicine to the expression of cell adhesion molecule in experimental otitis media with effusion].

35. [Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999].

36. Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan.

37. [Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].

38. Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor.

39. Clinical and pro-host effects of cefaclor in prophylaxis of recurrent otitis media in HIV-infected children.

40. [The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].

41. Assumed versus approved breakpoints.

42. Cefaclor, a cephalosporin antibiotic, delays gastric emptying rate by a CCK-A receptor-mediated mechanism in the rat.

43. The efficacy and safety of cefaclor in respiratory infections amongst Pakistani children.

44. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.

45. Assessment of the susceptibility of Streptococcus pneumoniae to cefaclor and loracarbef in 13 countries.

46. E test for studying in vitro activity of seven antimicrobial agents against penicillin-susceptible and penicillin-resistant pneumococci.

47. Presence of ROB-1 beta-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae.

48. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.

49. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.

50. Control of c-fos expression in STC-1 cells by peptidomimetic stimuli.

Catalog

Books, media, physical & digital resources